Introduction"suspended" (Appendix) . 20 Trials that were registered more than 60 days after the start 1 date were excluded in order to avoid biases in the sample related to investigator decisions 2 after initial trial findings. 13 
4
The ClinicalTrials.gov query was performed on a single day (February 2 nd , 2015) in order 5 to account for ongoing updates to database records. The Institutional Review Board at 6 Boston Children's Hospital determined that this study was exempt from review. 7
. 8
Definitions and data characterization 9
Definitions for data elements in ClinicalTrials.gov were used as per the Glossary of (Appendix). Certain data elements were further categorized for the purposes of our 12
analysis. 13 14
All conditions under study were classified using a modified version of the 2010 Global 15
Burden of Disease hierarchical disease and injury cause list. 22 The age of study 16 participants was categorized into "preterm, newborn, and infant," "toddler and 17 preschool," "school age," "adolescent," and "mixed ages" based on the age eligibility 18 criteria and the details provided in the trial description. 19
20
Organizations listed as sponsors and collaborators of a study are considered the funders 21 of the study (see Appendix). In cases where more than one sponsor is listed, the lead 22 sponsor is considered to be the primary funder. 20, 21, 23 Primary funding sources are 23 categorized in ClinicalTrials.gov as industry, government (NIH and other US Federal 24 agencies), or "other", which includes academic institutions, non-profit research networks, 1 and non-US government sponsors. We reviewed all trials that were designated as "other" 2 and identified those that were funded by an academic institution in order to create a new 3 funding variable. Trials were therefore considered to be funded by "industry", "academic 4 institutions", or "other", which included all government-funded trials (including non-US 5 federal agencies), as well as the remaining trials originally labeled as "other". 6 7 Trials were characterized as small (<100 participants), mid-size (100-499 participants), or 8 large (>500 participants). 13 Archived entries of each trial were queried to extract the 9 planned enrollment figures prior to commencement of subject recruitment and the actual 10 number of enrolled participants at the time of trial completion or discontinuation. 24 
12
Time to publication was defined as the interval between "primary completion date" 13 (Appendix) and the date the publication appeared in print or as an electronic publication, 14 whichever occurred first. If the primary completion date was missing (n=2), the study 15 "completion date" was used. 25 
17
Reasons for trial discontinuation were tabulated based on data provided in 18 ClinicalTrials.gov entries and email correspondence with study investigators when this 19 information was missing or unclear. Conduct problems were defined as technical or 20 logistical issues compromising trial completion. Difficulties with obtaining approval by 21 institutional review boards or other regulatory bodies were considered regulatory issues. 22
Trial discontinuation due to safety or efficacy findings, or changes in standard of care 23 were considered informative terminations. 
Publication search 2
All trial entries were reviewed to identify publications automatically added to the trial 3 record via the national clinical trial (NCT) identifier number. If a publication was not 4 listed in the publication field of the entry, Medline was searched via PubMed 5 independently by both authors (NP and FB) using NCT number, trial title, author names, 6 institutions and study keywords. Articles were linked to the corresponding trials based 7 on comparison of the trial data provided in the registry entry and in the abstract or full 8 manuscript, when necessary. If a publication was not identified in Medline, the same 9 search protocol was used in EMBASE and GoogleScholar. For industry-sponsored trials, 10 we also reviewed company websites for information on trial publications. 11
12
If we were unable to match a trial to a publication, we attempted to contact study 13 investigators and sponsors to inquire about publication status. Email addresses were 14 collected from the registry entries and from previous publications by the investigators. A 15 standardized email was sent, with one follow-up email if no response was received. 12 For 16 trials that listed only a sponsoring company name, responsible individuals were contacted 17 by email, online form, or telephone as per company website instructions. 18
19
We considered a trial published if it was associated with a peer-reviewed manuscript 20 describing trial findings.
12,13 Trials were considered unpublished if we were unable to 21 identify a publication and trial investigators informed us that the trial was unpublished, 22
did not respond to our inquiries, or did not have valid contact information that we were 23 able to locate.
12 A final search for all trials without publications was completed on 24 September 1, 2015, allowing for a minimum of 32 months for manuscript submission, 1 review and publication. 2 3
Statistical analyses 4
Chi-Square tests were used to assess associations between trial characteristics and trial 5 completion and publication status. We used logistic regression models to assess the 6 impact of primary funding source on trial discontinuation and on trial non-publication at 7 24 and 36 months after trial completion, controlling for trial design variables previously 8
shown to impact trial completion and eventual publication.
12-14 These variables were 9 pre-specified and included intervention type, age of study participants, masking, and 10 sample size. Age of study participants was not found to be significant in any of the 11 models and was dropped from the final models in order to minimize overfitting. This did 12 not substantially change the results. Student's t-test was used to compare time to 13 publication according to funding source. Statistical significance was set at P-value <0.05. 14 All statistical analyses were conducted using SAS (version 9.4, SAS Institute, Inc, Cary, 15
NC). 16 17

Results
18
Trial characteristics 19
We identified 559 randomized pediatric clinical trials that met inclusion criteria for our 20 analysis (Figure 1) . Nearly a quarter of all trials studied childhood vaccines and another 21 8% examined other interventions for common childhood infectious diseases (Table 1) . 22 Drugs/biologics (67.8%) were the most frequently investigated interventions (Table 2) . 23
The predominant sources of funding were academic institutions (43.8%) and industry 24 (48.7%). Fifty-three percent of trials were designed as double-blind studies with 33.5% 1 conducted as open label trials. The median planned sample size was 159 (interquartile 2 range [IQR] 60-424) with 37.9% of trials anticipating enrollment of less than 100 3 participants and 21.5% planning to enroll greater than 500 participants. 4
5
Discontinuation of pediatric clinical trials 6
A total of 104 trials (19%) were discontinued. Thirty-six were withdrawn prior to 7 participant recruitment while 5 were suspended and 63 terminated after participants had 8 already been enrolled. In total, an estimated 8,369 children were enrolled in trials that 9 were never completed. Patient accrual (n=38, 36.5%) was cited to be the most common 10 reason, followed by conduct problems (n=13, 12.5%) and informative termination, (n=13, 11 12.5%). Notably, funding issues were the least likely to be cited as reasons for trial 12 discontinuation (n=5, 4.8%) ( Table 3) . 13
14
In univariate analyses, primary funding source (P=0.044), and planned sample size 15 (P<0.001) were found to be significant determinants of trial discontinuation (Table 2) . 16
Fewer trials funded by industry were discontinued (39.4%) compared to those with 17 academic affiliations (54.8%). In multivariate analysis, funding source and sample size 18 remained significant determinants of trial discontinuation (Table 4) . Trials primarily 19 funded by industry were less likely to result in discontinuation compared to those funded 20 by academic sources (odds ratio [OR] 0.46, 95% CI 0.27 to 0.77, P=0.004). Larger trials 21
were also less likely to be discontinued (OR 0.999, 95% CI 0.998 to 1.0). 22 23
Non-publication of pediatric clinical trials 24
Among all trials that were completed, 136 (29.8%) remained unpublished after a mean of 1 58 months between trial completion and publication search. These trials accounted for an 2 estimated 69,165 pediatric trial participants, representing 27% of the total study 3 population among completed trials. Among these unpublished trials, 42 (30.8%) had 4 results posted in the registry. 5 6
In univariate analyses, intervention type and primary funding source were found to be 7 associated with non-publication at 24 months; at 36 months, primary funding source was 8 associated with non-publication (Table 5) . In multivariate analyses, industry funding was 9 associated with a greater than two-fold increase in the odds of non-publication at 24 10 months compared to academic institutions (OR 2.21, 95% CI 1.35-3.64; P=0.002) and a 11 greater than three-fold increase at 36 months (OR 3.12, 95% CI 1.60-6.08, P<0.001) 12 (Table 6) . 13
14
The mean time to publication for all trials was 29 months (95% CI, 28 to 31 months), 15 with a longer mean time to publication for trials funded by industry compared to 16 academic institutions (33 months vs 24 months, respectively, P<0.001). 17
18
Discussion 19
Our study demonstrates that amongst interventional trials conducted in children, trial 20 discontinuation and non-publication are common. We found that 19% of trials were 21 discontinued, two-thirds of which had already enrolled participants at the time of trial 22 termination. Poor recruitment and problems with the conduct of the trial were among the 23 most commonly reported reasons for trial discontinuation. Furthermore, after a mean of 24 58 months since completion, 30% of trials remained unpublished. In all, greater than 1 69,000 children, representing nearly a third of the total population enrolled in completed 2 trials, were exposed to interventions without subsequent publication of trial findings. Our 3 study shows that trial sponsors were an important determinant of these outcomes, with 4 trials funded by industry less likely to be discontinued but more likely to remain 5 unpublished 24 and 36 months after trial completion. 6 7 Children have historically been under-represented in clinical trials compared to adults 8 and a number of FDA policies aim to incentivize and increase the study of interventions 9 in pediatric populations. These include the Best Pharmaceuticals for Children Act and 10 the Pediatric Research Equity Act, which have been credited with increasing the number 11 of pediatric drug trials and the number of drug labels that contain pediatric safety and 12 efficacy information. 18, 27, 28 Our findings indicate that once trials are initiated, additional 13 focus is needed to maximize the knowledge gain from pediatric trial participation. 14 15 A number of trials were discontinued for reasons considered informative, including 16 preliminary safety and efficacy findings or changes in the standard of care that occurred 17 after the trial had been initiated. Such termination likely prevents further wasted 18 resources and may be unavoidable at a certain baseline rate. However, there may be 19 opportunities to reduce non-informative trial discontinuation, such as poor patient accrual 20 and technical or logistical issues with trial conduct. Difficulties with trial enrollment 21 have been previously documented among adult trials and cited as the most common 22 factor for trial discontinuation. 12, 14, 26 The rate of discontinuation of pediatric trials (19%) 23 was comparable to rates found in adult populations (21-25%), 12, 14 indicating that the 24 potential challenges encountered with pediatric patient recruitment do not appear to 1 increase the odds of trial discontinuation. 2 3 Trials sponsored by industry were less likely to be discontinued. This may be related to 4 additional financial and human resources available in industry-funded trials, such as 5 research coordinators to manage patient recruitment or technical infrastructure to 6 facilitate trial conduct. For academic trials in particular, investigators and research 7 oversight committees should be accountable for ensuring that clinical trials are feasible 8 and have the material and human resources available to achieve the proposed goals. 9
10
The non-publication of trial findings represents a violation of the ethical imperative to 11 share results of trials that involve human subjects and, further, introduces publication bias 12 into the medical literature.
1,4-6 Non-publication has been examined across a range of 13 different trial types, with rates predominantly between 25% and 35%.
12-17 This is 14 consistent with our findings of a non-publication rate of 30%. Trial non-publication is 15 particularly concerning given the limited availability of volunteers for clinical trials and 16 the high rates of trial termination due to difficulties in participant accrual. Similar to 17 prior work, we found that industry sponsorship was associated with non-publication and 18 delay in publication of trial results. 6, [12] [13] [14] 16, 17 However, non-publication was also high for 19 trials funded by academic institutions, which arguably have an even greater mandate to 20 uphold the standards of clinical trial reports underpinning evidence-based clinical 21 decision making. This finding is in accordance with previous work that has shown poor 22 rates of dissemination of clinical trial findings across leading academic medical centers. The Declaration of Helsinki -the central document governing regulation of human 2 subjects research -states that investigators are responsible for the public dissemination of 3 trial results involving human participants, regardless of the findings. 3 There is some 4 evidence that trial registration has contributed to an increase in the publication of trials 5 with negative results, thus curbing publication bias related to preferential reporting of 6 positive findings. 10, 11 However, given persistent high rates of trial non-publication across 7 funding types, additional mechanisms are needed to increase trial publication or make 8 trial results publicly available in order to facilitate analysis and reporting by other 9
investigators. One such initiative is RIAT-Restoring Invisible and Abandoned Trials-10 which has garnered support from a number of high-profile journals. 30 This proposal 11 invites researchers with unpublished trials to signal their intent to publish the trial within 12 a year or else provide public access to their trial results and offer the opportunity to 13 independent investigators to become "restorative authors".
31,32
15
It is of note that the FDA Amendments Act (FDAAA) of 2007 requires study results to be 16 reported, but does not specifically require publication. Trials can therefore fulfill this 17 mandate through results reporting in ClinicalTrials.gov. While any dissemination of 18 results has value, we chose to focus on whether trial results were published in peer-19 reviewed journals, as this represents the most widely accessible and commonly used 20 information source for physicians seeking to apply trial results to their clinical practice. 21
The peer review process also ensures that trial results are rigorously scrutinized and 22 ensures appropriate interpretation of the results. 23 24 Several limitations should be noted when interpreting our findings. This study analyzed 1 only trials registered in ClincialTrials.gov and it is possible that there were additional 2 pediatric interventional trials that were not captured in our analysis. The rate of non-3 registration of pediatric trials is unknown, but it is unlikely that these trials would have a 4 higher rate of completion or publication given federal and editorial policies mandating 5 registration. It should also be noted that information in the registry is provided by 6 investigators and sponsors and we were not able to verify the accuracy of the trial data. 7
This issue is mitigated in part by automated data validity checks and manual review by 8
ClinicalTrials.gov staff to ensure data accuracy prior to public posting. 33 There were 9 missing data in the registry such as trial phase and reasons for trial discontinuation, which 10 we were unable to complete despite efforts to contact investigators. Finally, it is possible 11 that we did not identify all publications associated with trials in our cohort. However, we 12 employed a rigorous approach, consisting of a standardized search protocol applied to 13 three separate publication databases and performed by two investigators, independently. 14 These searches were further augmented with investigator queries, making missed 15 publications unlikely. 
